Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata) on February 2, 2012. The report serves as a Regulation FD disclosure regarding the presentation of clinical data at the ASCO 2012 Genitourinary Cancers Symposium.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements or quantitative financial data.
Material Changes
There are no material financial changes reported in this document. The material event is the dissemination of new clinical data regarding the company's lead candidate, OGX-427.
Guidance, Outlook, and Management Commentary
- Clinical Data Presentation: The company presented data on OGX-427 at the ASCO 2012 Genitourinary Cancers Symposium.
- Prostate Cancer: Data provided ongoing evidence of Hsp27 as a potential therapeutic target in advanced prostate cancer.
- Bladder Cancer: A Phase 1 study showed early evidence of activity in bladder cancer.
- Regulatory Status: The information in this report is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the full text of the press releases attached as Exhibit 99.1 and Exhibit 99.2 for specific clinical trial results.
- Confirm the current status of the OGX-427 development program and any subsequent regulatory filings.
- Review the company's most recent 10-K or 10-Q for actual financial position, cash runway, and liquidity metrics, as this 8-K contains none.
- Monitor for any future updates on the Phase 1 study in bladder cancer and the Hsp27 target validation.